S12E4: The science behind three-month Octreotide formulation

In today's podcast, we talk to Anne Vaslin Chessex,  Global Program Leader at  Debiopharm International. In this dynamic chat, we explore Debiopharm's innovative three-month formulation of Octreotide for acromegaly, highlighting the science, clinical trials, and patient benefits. Gain insights into drug development, patient-centered approaches, future treatment options, and learn how to participate in the clinical trial. Dr. Vaslin Chessex has a PhD in Neurosciences and currently oversees the global strategy for drug development programs in rare diseases.  This is a fascinating talk about the science and expertise behind long-acting formulations, patient needs in acromegaly, treatment challenges, and the specifics on the clinical trial design, sites, and recruitment.